@language:english – DEARGEN UPDATES

2022년 12월 14일2023년 1월 5일

KMEDIhub-Deargen announced their co-development agreement

Deargen and KMEDIhub conducted co-developemnt for new drug discovery AI platform.

2022년 10월 6일2023년 1월 5일

JW Pharmaceutical agreed to collaboration with Deargen by using Deargen’s AI solution to develop new drugs

Deargen announced on 6th that they agreed to collaborate with JW pharmaceutical to develop innovative new drugs via Deargen’s AI model.

2022년 7월 26일2022년 8월 16일

Deargen begins full operation of iDear Center for AI-convergence drug development

Deargen has completed the end-to-end AI drug development platform ‘DEARGEN iDeas” to serve as a high-quality data productino for advancing its platform.

2022년 6월 10일

[Interview] “Deargen enhances its pipeline to accelerate the AI-powered new drug development.”

Inhwan Bae, CDO of Deargen, said through the iDear Center that Deargen will enhance the preclinical pipeline and be in full swing of innovative drug development.

2022년 5월 3일2022년 5월 3일

“AI drug discovery companies should have technical skills and mid-to-long-term business model.”

One of the most significant business models for AI drug development companies is collaborating with global companies..

2022년 3월 31일

Deargen-NeogenTC, Announced a research collaboration on developing an AI platform for cancer immunotherapy.

Deargen starts a research collaboration with NeogenTC to develop a TCR-T treatment prediction platform using Deargen’s sequence-based AI technology.

2022년 3월 24일2022년 3월 31일

제6기 결산공고

2022월 03월 24일 디어젠 주식회사 대표이사 강 길 수

2022년 3월 16일2022년 3월 17일

[Interview] “Dongtan RnD Center, iDear Center, will be an outpost of anti-cancer drugs”

The first interview article on Kilsoo Kang, CEO of Deargen, after he successfully secured the SeriesB funding round.

2022년 3월 16일2022년 3월 16일

Deargen, Accepted its research paper at AAAI Conference…“Introducing a new model for enhancement of estimation of certainty in new drug candidates.”

Deargen presented a new AI technology on ‘enhanced model on estimating certainty in new drug candidates.’

2022년 3월 2일2022년 3월 2일

Sequence Based, AI-Driven Drug Discovery Company, Deargen Raises US$17 Million in SeriesB Financing Round to Accelerate In-House Pipeline

Will establish a 2,600m2 AI convergence new drug development center (iDear Center) and accelerate internal new drug development